Skip to main content

Glitazone may Lower the Incidence of Parkinson's Disease

 

Clinical courses

Parkinson's disease (PD) is a chronic and progressive disorder of the central nervous system that affects movement. It is often characterized by tremors. Researchers have now found a link between a class of drugs used to treat diabetes and protection against PD. The study published  in PLOS Medicine.

The study conducted by Dr. Ruth Brauer, of the London School of Hygiene & Tropical Medicine, found a lower incidence of PD among patients using a glitazone drug (either rosiglitazone or pioglitazone) to treat diabetes when compared to patients who had used different treatments for diabetes. The study findings are consistent with animal and in vitro studies which suggested that glitazones and other drugs that target peroxisome proliferation-activated receptor gamma may have neuroprotective effects.

Besides, glitazones have been associated with serious side effects. However, the researchers are hopeful that these findings may pave the way towards other treatments that target the same pathway.


<< Pharma News

Subscribe to PharmaTutor News Alerts by Email >>